company background image
NYMX

Nymox Pharmaceutical NasdaqCM:NYMX Stock Report

Last Price

US$0.46

Market Cap

US$40.5m

7D

4.8%

1Y

-72.0%

Updated

27 Jun, 2022

Data

Company Financials
NYMX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

NYMX Stock Overview

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally.

Nymox Pharmaceutical Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nymox Pharmaceutical
Historical stock prices
Current Share PriceUS$0.46
52 Week HighUS$2.27
52 Week LowUS$0.35
Beta1.14
1 Month Change9.83%
3 Month Change-64.52%
1 Year Change-72.04%
3 Year Change-67.28%
5 Year Change-88.99%
Change since IPO-92.73%

Recent News & Updates

Shareholder Returns

NYMXUS BiotechsUS Market
7D4.8%10.3%6.6%
1Y-72.0%-24.3%-18.4%

Return vs Industry: NYMX underperformed the US Biotechs industry which returned -24.3% over the past year.

Return vs Market: NYMX underperformed the US Market which returned -18.4% over the past year.

Price Volatility

Is NYMX's price volatile compared to industry and market?
NYMX volatility
NYMX Average Weekly Movement22.1%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: NYMX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.

Volatility Over Time: NYMX's weekly volatility has increased from 16% to 22% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1989n/aPaul Averbackhttps://nymox.com

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

Nymox Pharmaceutical Fundamentals Summary

How do Nymox Pharmaceutical's earnings and revenue compare to its market cap?
NYMX fundamental statistics
Market CapUS$40.51m
Earnings (TTM)-US$15.18m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NYMX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$15.18m
Earnings-US$15.18m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.17
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NYMX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is NYMX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NYMX?

Other financial metrics that can be useful for relative valuation.

NYMX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-2.7x
PEG Ration/a

Price to Book Ratio vs Peers

How does NYMX's PB Ratio compare to its peers?

NYMX PB Ratio vs Peers
The above table shows the PB ratio for NYMX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average22.6x
AIKI AIkido Pharma
0.3x-28.3%US$30.7m
INFI Infinity Pharmaceuticals
6.6x-1.5%US$65.5m
ENZN Enzon Pharmaceuticals
6xn/aUS$24.3m
AURX Nuo Therapeutics
77.9xn/aUS$41.1m
NYMX Nymox Pharmaceutical
n/an/aUS$40.5m

Price-To-Book vs Peers: NYMX is good value based on its Price-To-Book Ratio (-29.2x) compared to the peer average (22.7x).


Price to Earnings Ratio vs Industry

How does NYMX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: NYMX is good value based on its Price-To-Book Ratio (-29.2x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is NYMX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NYMX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-30x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NYMX's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of NYMX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NYMX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NYMX's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NYMX's PEG Ratio to determine if it is good value.


Discover undervalued companies

  • Take a look at our analysis of NYMX's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Future Growth

How is Nymox Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


11.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nymox Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of NYMX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Past Performance

How has Nymox Pharmaceutical performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-0.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NYMX is currently unprofitable.

Growing Profit Margin: NYMX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NYMX is unprofitable, and losses have increased over the past 5 years at a rate of 0.5% per year.

Accelerating Growth: Unable to compare NYMX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NYMX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: NYMX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is Nymox Pharmaceutical's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NYMX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: NYMX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: NYMX is debt free.

Reducing Debt: NYMX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NYMX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: NYMX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 14.9% each year


Discover healthy companies

Dividend

What is Nymox Pharmaceutical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NYMX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NYMX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NYMX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NYMX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NYMX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.2yrs

Average management tenure


CEO

Paul Averback (70 yo)

26.75yrs

Tenure

US$1,407,838

Compensation

Dr. Paul Averback, M.D., D A.B.P., has been the President of Nymox Pharmaceutical Corporation since September 1995 and serves as its Chief Executive Officer. Dr. Averback is the Founder of Nymox Pharmaceut...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD1.41M) is above average for companies of similar size in the US market ($USD749.40K).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: NYMX's management team is seasoned and experienced (7.2 years average tenure).


Board Members

Experienced Board: NYMX's board of directors are seasoned and experienced ( 16 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: NYMX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.6%.


Top Shareholders

Company Information

Nymox Pharmaceutical Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Nymox Pharmaceutical Corporation
  • Ticker: NYMX
  • Exchange: NasdaqCM
  • Founded: 1989
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$40.509m
  • Shares outstanding: 90.28m
  • Website: https://nymox.com

Location

  • Nymox Pharmaceutical Corporation
  • Bay & Deveaux Streets
  • 2nd Floor
  • Nassau
  • Bahamas

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/27 00:00
End of Day Share Price2022/06/27 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.